Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058611 | 0.84 | CYP3A4 (0.61) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 | |
| SCHEMBL7832563 | 0.84 | CYP3A4 (0.57) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 | |
| SCHEMBL3696409 | 0.84 | TAAR1 (0.62) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 | |
| SCHEMBL3691129 | 0.84 | TAAR1 (0.62) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 | |
| SCHEMBL30320284 | 0.84 | TAAR1 (0.62) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 | |
| SCHEMBL16356746 | 0.84 | TAAR1 (0.62) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 | |
| SCHEMBL3098519 | 0.84 | TAAR1 (0.62) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL28561355 | 0.83 | CYP3A4 (0.59) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL28561354 | 0.83 | CYP3A4 (0.59) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 | |
| SCHEMBL25987895 | 0.83 | TAAR1 (0.59) | TAAR1SLC6A4CYP3A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176642-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | GYORKOS ALBERT (US) | 2003-09-18 | — | — | US | disclosed |
| US-6548638-B2 | Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. | CORTECH, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020010315-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | GYORKOS ALBERT (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1089752-A4 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6255453-B1 | INHIBITORS OF HUMAN NEUTOPHIL ELASTASE; TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK, MULTIPLE ORGAN FAILURE, PERIODONTAL DISEASE, GLOMERULONEPHRITIS, CYSTIC FIBROSIS; ANTIARTHRTITIC AGENTS | CORTECH, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-1089752-A1 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | Cortech Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6001813-A | Val-pro containing α-keto oxadiazoles as serine protease inhibitors | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999062538-A1 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010315-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | ELANE, SERPINB1, HPN | TAAR1 4800/4885SLC6A4 4264/4885CYP3A4 2734/4885 |
| US-20030176642-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | ELANE, SERPINB1, HPN | TAAR1 4800/4885SLC6A4 4264/4885CYP3A4 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.